J.P. Morgan discloses Kangji Medical share dealings amid privatization

On September 9, 2025, J.P. Morgan Securities PLC, an associate connected with the offeror, disclosed multiple dealings in Kangji Medical Holdings Limited shares. These transactions were part of a privatization by way of scheme of arrangement and were made for J.P. Morgan Securities PLC's own account, involving hedging of Delta 1 products created from wholly unsolicited client-driven orders.

The disclosed dealings included both sales and purchases. J.P. Morgan Securities PLC sold a total of 2,352 shares, with one transaction of 2,000 shares at a paid/received amount of $17,663.73, and another of 352 shares at $3,100.06. The highest price received for sales was $8.85.

Conversely, J.P. Morgan Securities PLC purchased a total of 234,500 shares. This included one transaction of 4,500 shares for $39,737.34 and another significant purchase of 230,000 shares for $2,027,208.04. The lowest price paid for purchases was $8.81. J.P. Morgan Securities PLC is ultimately owned by JPMorgan Chase & Co.